Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Intracellular Signaling Affects Focal Adhesions01:17

Intracellular Signaling Affects Focal Adhesions

3.8K
Integrins act both as extracellular input receivers and as intracellular processing activators. As their name suggests, integrins are entirely integrated into the membrane structure. Their hydrophobic membrane-spanning regions interact with the phospholipid bilayer's hydrophobic region. These membrane receptors provide extracellular attachment sites for effectors like hormones and growth factors. They activate intracellular response cascades when their effectors are bound and active.
Some...
3.8K
Formation of the Platelet Plug01:22

Formation of the Platelet Plug

10.7K
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
10.7K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

1.5K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.5K
Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

10.1K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
10.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Modulating cellular deformability via 3D dextran hydrogel cultivation to regulate the microcirculation of mesenchymal stem cells in murine spleen and liver.

Experimental and molecular pathology·2025
Same author

hsa_circ_0020093 suppresses ovarian cancer progression by modulating LRPPRC activity and miR-107/LATS2 signaling.

Biology direct·2024
Same author

Gene therapy for cross-correction of somatic organs and the CNS in mucopolysaccharidosis II in rodents and non-human primates.

Molecular therapy. Methods & clinical development·2023
Same author

Circular RNA hsa_circ_0007444 inhibits ovarian cancer progression through miR-23a-3p/DICER1 axis.

Acta biochimica et biophysica Sinica·2023
Same author

Plasma circRNA microarray profiling identifies novel circRNA biomarkers for the diagnosis of ovarian cancer.

Journal of ovarian research·2022
Same author

Efficacy, dose-response, and aerosol delivery of dry powder synthetic lung surfactant treatment in surfactant-deficient rabbits and premature lambs.

Respiratory research·2022

Related Experiment Video

Updated: Mar 28, 2026

A Uniform Shear Assay for Human Platelet and Cell Surface Receptors via Cone-plate Viscometry
04:32

A Uniform Shear Assay for Human Platelet and Cell Surface Receptors via Cone-plate Viscometry

Published on: June 5, 2019

8.3K

Blocking α5β1 Integrin Attenuates sCD40L-Mediated Platelet Activation.

Damir Simic1, Nancy Bogdan1, Fang Teng2

  • 11 Preclinical Development & Safety, Janssen Research & Development, LLC, Spring House, PA, USA.

Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
|January 1, 2016
PubMed
Summary

Soluble CD40L (sCD40L) binding to the novel platelet receptor α5β1 integrin triggers platelet activation. This finding advances our understanding of thrombotic disease mechanisms.

Keywords:
CD40 ligandand flow cytometryplatelet activationα5β1 integrin

More Related Videos

Analyzing Platelet Subpopulations by Multi-color Flow Cytometry
08:04

Analyzing Platelet Subpopulations by Multi-color Flow Cytometry

Published on: June 10, 2025

2.0K
Author Spotlight: Development of a Method for Identifying Small Molecular Antagonists of β2 Integrin Activation
04:15

Author Spotlight: Development of a Method for Identifying Small Molecular Antagonists of β2 Integrin Activation

Published on: February 2, 2024

2.4K

Related Experiment Videos

Last Updated: Mar 28, 2026

A Uniform Shear Assay for Human Platelet and Cell Surface Receptors via Cone-plate Viscometry
04:32

A Uniform Shear Assay for Human Platelet and Cell Surface Receptors via Cone-plate Viscometry

Published on: June 5, 2019

8.3K
Analyzing Platelet Subpopulations by Multi-color Flow Cytometry
08:04

Analyzing Platelet Subpopulations by Multi-color Flow Cytometry

Published on: June 10, 2025

2.0K
Author Spotlight: Development of a Method for Identifying Small Molecular Antagonists of β2 Integrin Activation
04:15

Author Spotlight: Development of a Method for Identifying Small Molecular Antagonists of β2 Integrin Activation

Published on: February 2, 2024

2.4K

Area of Science:

  • Cardiovascular Biology
  • Hematology
  • Immunology

Background:

  • Soluble CD40L (sCD40L) is a key mediator linking inflammation, hemostasis, and vascular dysfunction.
  • Platelet activation by sCD40L contributes to atherosclerosis and atherothrombosis.
  • Previously, CD40 and αIIbβ3 were considered the primary platelet receptors for sCD40L.

Purpose of the Study:

  • To investigate the functional role of α5β1 integrin as a novel platelet receptor for sCD40L.
  • To determine if the interaction between sCD40L and α5β1 integrin induces platelet activation.

Main Methods:

  • Utilized anti-α5β1 blocking antibodies in human whole blood assays.
  • Evaluated platelet activation in response to sCD40L and α5β1 integrin interaction.

Main Results:

  • Demonstrated that the interaction between sCD40L and α5β1 integrin leads to significant platelet activation.
  • Provided the first evidence for α5β1 integrin's role in mediating sCD40L-induced platelet activation.

Conclusions:

  • α5β1 integrin is a functional receptor for sCD40L on platelets.
  • This interaction contributes to platelet activation and potentially thrombotic events.
  • Understanding this pathway offers new insights into the etiology of thrombotic diseases.